Program
Liquid Metformin 250 mg/mL
Its studies are led by Aspargo Labs.
Furthest: phase 1, since Dec 10, 20254 company-led studies, 4 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aspargo Labs | 44 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2025First studies: 4 phase 1 studiesFirst studyNCT07300059, NCT07300046, NCT07300033 and 1 more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07300059Healthy Volunteers | 1 | Not yet recruiting | Aug 15, 2026 | 24 |
| NCT07300046Healthy Volunteers | 1 | Not yet recruiting | Aug 15, 2026 | 24 |
| NCT07300033Healthy Volunteer | 1 | Not yet recruiting | Jul 15, 2026 | 24 |
| NCT07300007Healthy Volunteer | 1 | Not yet recruiting | May 15, 2026 | 24 |
How it is read
Names in the registry
- “Liquid Metformin 250 mg/mL”, 4 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.